All In Biotech

Drug Trial Radar · NCT01454063

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study of the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

Last checked: Nov 20, 2026Latest source record: Aug 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 405 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

405

Actual

Start

Sep 2011

Primary completion

Mar 2012

Study completion Mar 2012

Sponsor

Lead sponsor
Omeros CorporationIndustry
Sponsor type
Industry
First posted
Oct 18, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of OMS302 (the study drug) for maintaining intraoperative mydriasis in individuals undergoing Intraocular Lens Replacement (ILR) surgery.

Conditions

  • Intraocular Lens Replacement

Interventions

  • OMS302Drug

    OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced salt solution (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.

  • PlaceboDrug

    Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Area-under-the-Curve (AUC) Analysis of Change From Baseline in Pupil Diameter (mm) During SurgeryTime frame: from surgery baseline (pre-incision) through surgery end (time of cortical clean-up/wound closure)

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Chandler, Arizona

  • Site not named

    Glendale, Arizona

  • Site not named

    Los Angeles, California

  • Site not named

    Cape Coral, Florida

  • Site not named

    Fort Myers, Florida

  • Site not named

    Stuart, Florida

  • Site not named

    Bloomington, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Washington, Missouri

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    New York, New York

  • Site not named

    Goodlettsville, Tennessee

  • Site not named

    Austin, Texas

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.